TCGA-C8-A8HR-01A-11R-A36F-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 14
- os_event
- false
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3W6-01A-12R-A22K-07 | — | A | 0.932 |
| 2 | SRR35579837 | — | D | 0.916 |
| 3 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.916 |
| 4 | DRR168555 | — | — | 0.909 |
| 5 | R83 | — | — | 0.907 |
| 6 | 20080031.TNBC | — | D | 0.902 |
| 7 | SRR23303731 | — | — | 0.899 |
| 8 | R139 | — | — | 0.898 |
| 9 | TCGA-BH-A6R9-01A-21R-A32P-07 | — | A | 0.895 |
| 10 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |